A loss of membrane potential weakens the proton-motive force available to ATP synthase. As a result, the enzyme has less driving force to support ATP formation, and oxidative phosphorylation becomes disrupted. This connects the electrical change to impaired energy metabolism, making depolarization a functional indicator rather than merely a structural observation of mitochondria.
Greater permeability allows the conditions that maintain the proton gradient to break down more readily, so the electrical potential can collapse faster. This mechanism is important when interpreting mitochondrial injury because it links membrane integrity with the speed and extent of depolarization. It also helps explain why permeability changes can intensify downstream metabolic dysfunction.
The association reflects its combined effects on energy production and mitochondrial function. Once the membrane potential is disrupted, ATP-generating oxidative phosphorylation is compromised, and the change can accompany processes leading to cellular injury or death. In medicine, this makes depolarization useful as a mechanistic readout when studying apoptosis rather than as an isolated electrical measurement.
Fluorescent membrane-potential indicators can track changes in the electrical state of mitochondria, while complementary biochemical assays provide additional evidence about associated mitochondrial function. Used together, these approaches help investigators determine whether a treatment, toxic exposure, or disease-related condition is linked to depolarization and assess the broader metabolic consequences of that change.
Fluorescence provides a way to follow membrane-potential changes, but it does not by itself capture every consequence of mitochondrial dysfunction. Adding biochemical assays allows researchers to examine the change alongside functional evidence. This combined strategy can make conclusions more informative when evaluating apoptosis, ischemic damage, toxic drug effects, or mitochondrial disorders.
It is useful when investigators need to assess mitochondrial involvement in apoptosis, ischemic damage, toxic drug effects, or mitochondrial disorders. The measurement can also support evaluation of therapeutic candidates by showing whether a treatment changes mitochondrial function. These applications connect a cellular readout with disease mechanisms and potential treatment effects.